Compare Brunswick Corporation (BC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brunswick Corporation vs Recursion Pharmaceuticals Inc — how do they compare? Brunswick Corporation trades at $76.79 (market cap $5.04B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.78B). The key difference: Brunswick Corporation is far larger — about 2.8× Recursion Pharmaceuticals Inc's market cap, and Brunswick Corporation pays a 2.27% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BC | RXRX | |
|---|---|---|
Market Cap | $5.04B | $1.78B |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $6.79 |
52-Week Low | $56.64 | $2.84 |
Enterprise Value | $7.20B | $1.19B |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BC's stock trades at $76.95, down 1.22% on the day, with a bearish technical signal and support near $76. The company reported a net loss of $137.30 million in 2025 despite revenue of $5.36 billion, though recent earnings beat expectations. Analyst consensus is strongly bullish with a $86.40 price target, and the company continues expanding its Freedom Boat Club business.
The outlook is mixed: strong analyst support and operational cash flow of $562.10 million in 2025 provide upside potential, but negative profit margins and high P/E of 73.92 pose valuation risks. Investors face headwinds from profitability challenges despite positive sentiment from Wall Street.
RXRX trades at $3.30, down 7.3% today, with bearish technical signals from moving averages and oscillators. The clinical-stage biotech shows severe financial strain with a -851.51% net income margin and negative cash flow from operations of -$372M in 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights AI-driven drug discovery potential but questions commercial viability.
Despite analyst consensus price target of $7.83 suggesting 137% upside, high cash burn and unproven business model pose substantial risk. Investment appeal hinges on successful drug development milestones, but current fundamentals indicate speculative positioning suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
